Abstract
Interleukin 12 (IL-12), a heterodimeric cytokine, promotes an effective antitumor response against tumors of various histological types when delivered systemically as a protein or locally by gene transfer. We investigated parameters that influenced the effectiveness of IL-12 retroviral-mediated gene therapy of cancer in animals using the murine breast cancer line TS/A. Syngeneic fibroblasts (TIB80), stably transduced with a retrovirus expressing murine IL-12, were used for peritumoral injection. Injection of fibroblasts into established tumors resulted in complete regression of tumor in 40% of animals in a dose dependent manner when treated on day 4, and 20% when treated on day 8. Significant inhibition of growth of day 21 and day 40 tumors was observed following peritumoral injection of IL-12-expressing fibroblasts in a dose-dependent manner. Delivery of IL-12 by syngeneic fibroblasts at a tumor site is effective in eradicating established, weakly immunogenic TS/A tumors.
Original language | English (US) |
---|---|
Pages (from-to) | 53-58 |
Number of pages | 6 |
Journal | Experimental and Molecular Medicine |
Volume | 29 |
Issue number | 1 |
DOIs | |
State | Published - 1997 |
Externally published | Yes |
Keywords
- Cancer
- Gene therapy
- Interleukin-12